Xencor Partners with Merck in Antibody Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Xencor Partners with Merck in Antibody Technology
The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies.


Xencor, a biopharmaceutical company specializing in antibody engineering technology, has entered into a technology license and option agreement to provide Merck & Co. access to one of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody.

Under the agreement, Merck will be granted a nonexclusive license to a Xencor patent for use in an undisclosed product as well as an option to license the same intellectual property for future products. Xencor will receive an upfront payment and annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates as well as royalties on sales of any potential products that may result from this agreement, according to a Xencor statement.

Xencor engineers biotherapeutics using its proprietary Protein Design Automation technology platform, which is used in antibody engineering to improve antibody half-life, immune-regulatory function, and potency. The company is advancing multiple proprietary XmAb antibody drug candidates in the clinic, including XmAb5871 targeting CD32b and CD19 for autoimmune diseases, and the anti-CD30 candidate XmAb2513 for the treatment of Hodgkin’s lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for improved half-life and dosing schedules. Xencor has partnerships with Amgen, Pfizer, Janssen R&D, MorphoSys, Boehringer Ingelheim, CSL, and Human Genome Sciences (now part of GlaxoSmithKline). In these partnerships, Xencor is applying its proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency, according to company information.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here